All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
July 2024: Supporting information added for switching of rapid-acting human insulin analogues to biosimilars
News
July 2024: Supporting information added for switching of rapid-acting human insulin analogues to biosimilars
Section 6.1.1.1 Short-acting insulins has been updated to support switching of rapid-acting human insulin analogues to biosimilars where available; i.e. Novorapid (insulin aspart) to Trurapi, (biosimilar insulin aspart), and Humalog (insulin lispro) to Admelog (biosimilar insulin lispro).
NICE NG17 and NICE NG28 recommend when starting an insulin for which a biosimilar is available, the product with the lowest acquisition cost should be used. When people are already using an insulin for which a lower cost biosimilar is available, discuss the possibility of switching to the biosimilar. NHS Devon Medicines Optimisation Team have produced supporting information and prescribing guides for clinicians and patient information leaflets to support the change.
See here for more recent updates to the formulary.
